LAUSR

Abstract This study focused on testing manufactured silver nanoparticles (AgNPs) against the malaria pathogen Plasmodium falciparum and the malaria vector Anopheles stephensi using the plant filtrate from Madhuca longifolia. The M. longifolia leaf extracts were used to synthesize the AgNPs, which were then subjected to several physicochemical methods to determine their characteristics. To evaluate the effectiveness of the green produced AgNP therapy, the mosquitocidal activity of A. stephensi, cytotoxicity assay in Vero cells, and antiplasmodial activity assay were performed. The larval and pupal toxicity of biosynthesized AgNPs against the malarial vector A. stephensi is 90% promising in laboratory settings at low dosages (10 ppm). When tested on African green monkey kidney cells, the cytotoxic effect of biosynthesized materials was found to be inappropriately damaging up to 100 g·mL−1. The antimalarial efficacy of AgNPs was evaluated against P. falciparum strains. The parasites that were restrained by AgNPs at 100 ppm had the highest parasitemia restraint rate (80.4%). AgNPs then showed significant in vitro antimalarial activity against P. falciparum. Our findings suggested that the biosynthesized AgNPs might function as a novel antimalarial agent that is both safer for the environment and a barrier to infections spread by mosquitoes. Graphical abstract Illustration of AgNP synthesis in the fight against malaria.